Evidence map›Paper›PMID 38716066›Full record

ReviewAnalytical science advances2023

Blood microsampling technologies: Innovations and applications in 2022.

Manchu Umarani Thangavelu, Bert Wouters, Alida Kindt, Irwin K M Reiss, Thomas Hankemeier

Registry-linked trialAbstract readReview
In one paragraph

Review in Analytical science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06939556 (Development of a High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06939556 recruitingnot on this mapstarted 2025, after this paper: background citation

Development of a High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts

TypeobservationalSponsorIstituto Zooprofilattico Sperimentale delle VenezieRan2025 to 2025Enrolled152ConditionsDiagnostics, Pandemic Response
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Dried Blood Spots to Assess Cardiovascular-Kidney-Metabolic Health.Journal of the American Heart Association · 2025
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. RPLC- and HILIC-based non-targeted metabolomics workflow for blood microsamples.Metabolomics : Official journal of the Metabolomic Society · 2026
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Manchu Umarani ThangaveluMetabolomics and Analytics Centre Leiden University Leiden The Netherlands.ORCID https://orcid.org/0000-0003-2139-3846
Bert WoutersMetabolomics and Analytics Centre Leiden University Leiden The Netherlands.
Alida KindtMetabolomics and Analytics Centre Leiden University Leiden The Netherlands.ORCID https://orcid.org/0000-0001-6551-6030
Irwin K M ReissDepartment of Neonatal and Pediatric Intensive Care Division of Neonatology Erasmus MC Rotterdam The Netherlands.
Thomas HankemeierMetabolomics and Analytics Centre Leiden University Leiden The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the development of highly sensitive bioanalytical techniques, the volume of samples necessary for accurate analysis has reduced. Microsampling, the process of obtaining small amounts of blood, has thus gained popularity as it offers minimal-invasiveness, reduced logistical costs and biohazard risks while simultaneously showing increased sample stability and a potential for the decentralization of the approach and at-home self-sampling. Although the benefits of microsampling have been recognised, its adoption in clinical practice has been slow. Several microsampling technologies and devices are currently available and employed in research studies for various biomedical applications. This review provides an overview of the state-of-the-art in microsampling technology with a focus on the latest developments and advancements in the field of microsampling. Research published in the year 2022, including studies (i) developing strategies for the quantitation of analytes in microsamples and (ii) bridging and comparing the interchangeability between matrices and choice of technology for a given application, is reviewed to assess the advantages, challenges and limitations of the current state of microsampling. Successful implementation of microsampling in routine clinical care requires continued efforts for standardization and harmonization. Microsampling has been shown to facilitate data-rich studies and a patient-centric approach to healthcare and is foreseen to play a central role in the future digital revolution of healthcare through continuous monitoring to improve the quality of life.

Indexed as

dried blood spotforensic toxicologymicrosamplingtherapeutic drug monitoringvolumetric absorptive microsampling

Identifiers

PMID38716066
PMCPMC10989553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.